RFMx
Outpatient AFib Care Pathway
Clinical Protocol · v1.0
ACC/AHA/HRS 2023 · ESC 2024 · STS 2023
Outpatient Cardiovascular Clinic · AFib Population Management

From clinic identification to same-day procedural care — a structured pathway for atrial fibrillation.

A closed-loop, guideline-driven workflow that identifies AFib patients in outpatient cardiovascular clinics, risk-stratifies them for stroke and symptom burden, and routes appropriate candidates to ASC-based ILR, pacemaker, AV-node ablation, PVI/AF ablation, and LAA occlusion procedures.

1 in 4
Lifetime AFib risk after age 40 in the US
0.7–0.9%
Contemporary major adverse event rate for AF ablation
>12M
Projected US AFib patients by 2030
§ 01 · Identification

Surfacing AFib patients in the outpatient cardiovascular clinic.

Structured EHR triggers, ECG/monitor ingestion, and symptom capture feed a prioritized clinic worklist.

Trigger Criteria · Clinic Worklist

1
ICD-10 I48.x on active problem listParoxysmal, persistent, long-standing persistent, or permanent AF.
2
12-lead ECG with documented AF/AFLConfirmed by clinician review — not auto-algorithm alone.
3
Holter / event / patch monitor positive≥30 seconds of AF on ambulatory rhythm monitoring.
4
Wearable / CIED alertPPG or atrial lead–detected AF flagged for confirmatory ECG.
5
Symptom capturePalpitations, fatigue, dyspnea, reduced exercise tolerance, presyncope.
6
Unexplained stroke / TIACryptogenic events routed to extended monitoring pathway.

Core Workup Before Risk Stratification

  • LabsCBC, CMP, TSH, BNP, coags; renal & hepatic function for anticoagulant selection.
  • TTEChamber size, LVEF, valvular disease, LA volume index — anchors rhythm- vs. rate-control decision.
  • ECGBaseline rhythm, conduction, pre-excitation; confirms automated monitor findings.
  • MonitorBurden quantification (paroxysmal vs. persistent) via 14–30 day patch or ILR when indicated.
  • H&PSymptoms (EHRA class), comorbidities, OSA screening, lifestyle & weight-loss candidates.
§ 02 · Risk Stratification

Stroke risk, bleeding risk, and symptom burden — scored at every visit.

Dual US/EU framework: CHA₂DS₂-VASc (ACC/AHA/HRS 2023) or CHA₂DS₂-VA (ESC 2024) for stroke; HAS-BLED for bleeding; EHRA class for symptoms.
Stroke

CHA₂DS₂-VASc / VA Score

ESC 2024 now endorses CHA₂DS₂-VA (sex category removed); ACC/AHA/HRS 2023 continues to use CHA₂DS₂-VASc. Both predict annual thromboembolic risk in non-valvular AFib.
C
Congestive heart failure / LVEF ≤40%
+1
H
Hypertension
+1
A2
Age ≥75 years
+2
D
Diabetes mellitus
+1
S2
Prior stroke / TIA / thromboembolism
+2
V
Vascular disease (prior MI, PAD, aortic plaque)
+1
A
Age 65–74 years
+1
Sc
Sex category (female) — VASc only
+1
0 (M) / 1 (F)No anticoagulationShared decision-making
1 (M) / 2 (F)Consider OACPatient-specific risk-benefit
≥2 (M) / ≥3 (F)OAC recommendedClass I indication
Bleeding
HAS-BLED — modifiable risk review
Hypertension (uncontrolled) +1
Abnormal renal / liver +1/+1
Stroke history +1
Bleeding history / predisposition +1
Labile INR +1
Elderly (>65) +1
Drugs (NSAIDs/APT) +1
Alcohol ≥8 drinks/wk +1
Score ≥3 flags need for closer follow-up and modifiable-risk intervention — not withholding of anticoagulation.
Symptom Burden
EHRA Symptom Class
I
No symptoms
IIa
Mild — normal activity unaffected
IIb
Moderate — activity bothered
III
Severe — activity limited
IV
Disabling
EHRA ≥ IIb + failed/intolerant AAD (or first-line in selected paroxysmal) → AF ablation candidacy.
§ 03 · Candidate Flow

From risk-stratified AFib patient to ASC procedural destination.

Decision gates map each patient to the appropriate electrophysiology procedure based on rhythm, symptom, and stroke-risk profile.
AFib in CV Clinic IDENTIFIED · STRATIFIED EHRA · CHA₂DS₂-VASc · HAS-BLED Dx / Burden Quantification NEEDED? Implantable Loop Recorder Cryptogenic stroke · low-burden AF Post-ablation surveillance MONITOR Rate vs Rhythm Control EHRA ≥ IIb? Pacemaker (PPM) Brady-AF · sick sinus · pauses Drug-induced bradycardia RATE · AV-Node Ablation Refractory rate · tachy-CMP Post-PPM or + CRT AF Ablation (PVI) Symptomatic parox / persistent First-line option · HFrEF benefit RHYTHM LAA Occlusion High stroke risk + OAC contraindication OAC CONTRA Ambulatory Surgery Center SAME-DAY DISCHARGE with selection protocol
Proc · 33285

Implantable Loop Recorder

Long-term subcutaneous rhythm monitor (up to ~3 yrs). Highest sensitivity for paroxysmal AF detection.
Cryptogenic stroke / TIA
Unexplained palpitations / syncope
Post-ablation recurrence surveillance
AF burden quantification
ASCSafe
Proc · 33206–33208

Permanent Pacemaker

Dual- or single-chamber PPM for bradycardia in AF or drug-induced brady during rate-control therapy.
Tachy-brady syndrome
Symptomatic sinus pauses ≥3 s
AV block from rate-control drugs
Enables safe rate-control titration
ASCSafe
Proc · 93650

AV-Node Ablation

Complete AV junction ablation with PPM/CRT backup for refractory rate control, especially in tachy-mediated CM.
Uncontrollable rate despite Rx
Tachycardia-induced cardiomyopathy
Prior PPM or CRT in situ
Rhythm control not feasible
ASCSafe
Proc · 93656

AF Ablation (PVI)

Pulmonary vein isolation via RF, cryoballoon, or PFA. Class I for symptomatic drug-refractory AF; Class IIa first-line in selected paroxysmal.
EHRA ≥ IIb symptoms
Failed / intolerant ≥1 AAD (or first-line)
HFrEF with AF (mortality benefit)
LVEF ≥35% preferred for ASC
ASCSelected
Proc · 33340

LAA Occlusion

Percutaneous device-based closure (Watchman FLX / Amulet) for stroke prevention when long-term OAC is contraindicated.
CHA₂DS₂-VASc ≥2
OAC contraindication or bleeding Hx
Non-valvular AF
Adequate life expectancy >1 yr
ASCSelected
§ 04 · Outpatient Surgery Center Safety

Evidence supports same-day ASC delivery for properly selected patients.

Multi-center contemporary data show major adverse event rates comparable to — or lower than — hospital outpatient departments.
Published Evidence · 2023–2025

AF ablation in an ambulatory surgery center is feasible and safe with standardized protocols.

476
Ambulatory AF ablations (AHVI, 6.3 yrs)
1.5%
Major perioperative events (7/476)
4.9 → 0.9%
SAE rate trajectory 2010 → 2023

ASC Selection Criteria

Applied at pre-procedure visit. Patients failing any "exclude" criterion route to hospital outpatient department.
BMI < 40 kg/m² — airway and sedation manageable
LVEF ≥ 35% for AF ablation / LAAO candidates
ASA class I–III, no decompensated comorbidity
Stable anticoagulation with uninterrupted DOAC strategy
Hospital transfer agreement < 15 min — verified
Severe OSA without CPAP adherence
Mechanical valve, severe valvular disease, LA thrombus
Recent ACS / decompensated HF / active infection
No responsible adult for same-day discharge escort
§ 05 · Evidence Base

Guidelines and peer-reviewed data underpinning the pathway.

Key references

Summarized for clinical reference — see full text for complete recommendations and evidence grading.
'23
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation Joglar JA et al. Comprehensive US guideline endorsing CHA₂DS₂-VASc for stroke risk and providing Class I/IIa recommendations for catheter ablation. Circulation. 2024;149(1):e1–e156.
'24
2024 ESC Guidelines for the Management of Atrial Fibrillation Van Gelder IC et al. Introduces CHA₂DS₂-VA score (sex removed); recommends OAC for score ≥ 2 and consideration at ≥ 1. European Heart Journal. 2024;45(36):3314–3414.
'24
2024 EHRA/HRS/APHRS/LAHRS Expert Consensus Statement on Catheter and Surgical Ablation of AF Tzeis S et al. Defines complication criteria, procedural standards, and post-ablation management. Europace. 2024;26:euae083.
'23
STS 2023 Clinical Practice Guidelines for the Surgical Treatment of AF Wyler von Ballmoos MC et al. Class I for concomitant LAA occlusion in all AF patients undergoing first-time cardiac surgery. Ann Thorac Surg. 2024;118(2):291–310.
'23
Ablation of Atrial Fibrillation in an Ambulatory Outpatient Setting Willcox ME et al. 476-patient single-center ASC series — feasibility and safety demonstrated with same-day discharge protocol. Heart Rhythm O₂. 2023;4(8):478–482.
'25
Safety and Feasibility of Cardiac EP Procedures in Ambulatory Surgery Centers Aryana A et al. Multi-center analysis confirming low SAE rates for CA, CIED, TEE/DCCV, and AF ablation in ASC setting. Heart Rhythm. 2025;22:717–724.
'25
AF Catheter Ablation in a Day Surgery Center Outside the Hospital Setting Contemporary European cohort (450 pts, 2020–2024) demonstrating comparable safety to hospital outpatient delivery. Heart Rhythm. 2025. doi:10.1016/j.hrthm.2025.02.003
'22
Left Atrial Appendage Closure vs. Oral Anticoagulation (PRAGUE-17, 5-year) Osmancik P et al. Non-inferiority of LAAO to DOAC for composite stroke/cardiovascular events in high-risk AF patients. Eur Heart J. 2024;45(9):733–741.